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Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease that leads
to widespread motor neuron death, general palsy and respiratory failure. The most
prevalent sporadic ALS form is not genetically inherited. Attempts to translate therapeutic
strategies have failed because the described mechanisms of disease are based on
animal models carrying specific gene mutations and thus do not address sporadic
ALS. In order to achieve a better approach to study the human disease, human
induced pluripotent stem cell (hiPSC)-differentiated motor neurons were obtained from
motor nerve fibroblasts of sporadic ALS and non-ALS subjects using the STEMCCA
Cre-Excisable Constitutive Polycistronic Lentivirus system and submitted to microarray
analyses using a whole human genome platform. DAVID analyses of differentially
expressed genes identified molecular function and biological process-related genes
through Gene Ontology. REVIGO highlighted the related functions mRNA and DNA
binding, GTP binding, transcription (co)-repressor activity, lipoprotein receptor binding,
synapse organization, intracellular transport, mitotic cell cycle and cell death. KEGG
showed pathways associated with Parkinson’s disease and oxidative phosphorylation,
highlighting iron homeostasis, neurotrophic functions, endosomal trafficking and ERK
signaling. The analysis of most dysregulated genes and those representative of the
majority of categorized genes indicates a strong association between mitochondrial
function and cellular processes possibly related to motor neuron degeneration. In
conclusion, iPSC-derived motor neurons from motor nerve fibroblasts of sporadic
ALS patients may recapitulate key mechanisms of neurodegeneration and may offer
an opportunity for translational investigation of sporadic ALS. Large gene profiling
of differentiated motor neurons from sporadic ALS patients highlights mitochondrial
participation in the establishment of autonomous mechanisms associated with sporadic
ALS.
Keywords: amyotrophic lateral sclerosis, sporadic ALS, induced pluripotent stem cells, motor neuron
differentiation, microarray
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Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative
disease that is characterized by a selective death of motor neurons
in the brain and spinal cord of adults, leading to rapid respiratory
muscle failure and patient death (Cleveland and Rothstein,
2001). Sporadic ALS is not genetically inherited and represents
approximately 95% of all ALS cases. A minority of cases are
familial forms and are associated with gene mutations (Gros-
Louis et al., 2006; Turner and Talbot, 2008).
The generation of transgenic animals that carry mutated
human genes associated with familial ALS, for instance
superoxide dismutase (SOD1), tar DNA protein 43 (TDP-
43), fused in sarcoma, and valosin-containing protein genes,
has allowed the identification of basic mechanisms underlying
neurodegeneration in the disease (McGoldrick et al., 2013). In
fact, distinct processes of motor neuron death that are related to
toxic glial paracrine (Nagai et al., 2007; Gowing et al., 2009) and
autocrine (Ringer et al., 2012) signaling mechanisms have been
described using animalmodels. Furthermore, the early peripheral
pathological events of neuromuscular junction loss and motor
axon retraction, which may start long before symptom onset,
have also been described in these animal models (Rocha et al.,
2013; Venkova et al., 2014). Indeed, recent evidence has pointed
out the importance of close morphological and physiological
relationships between peripheral non-neuronal Schwann cells
(Keller et al., 2009; Chen et al., 2010; Maximino et al., 2014)
and fibroblasts (Raman et al., 2015) with motor axons, as key
participants in the early degeneration of motor neurons in ALS.
Despite significant progress, it is clear that shortcomings
remain with regard to recapitulating the processes underlying
the clinical form of sporadic ALS (Benatar, 2007b), based on
mechanisms described in transgenic models carrying specific
human gene mutations. Actually, these limitations inherent
in animal models have been considered the major obstacle
preventing the successful translation of results to clinical
practice. No therapy has been effective in counteracting human
disease progression or extending survival of ALS patients
(Benatar, 2007a). Moreover, there is a general consensus that the
development of therapeutic targets promoting positive clinical
results have been hampered by lack of a relevant human disease
model specific to sporadic ALS (Gordon and Meininger, 2011;
Veyrat-Durebex et al., 2014).
One of the most promising approaches to provide a better
understanding of the mechanisms underlying motor neuron
degeneration in sporadic ALS is the generation of specific
human-induced pluripotent stem cells (hiPSC) from fibroblasts
of motor nerves from sporadic ALS patients. These hiPSCs can
be differentiated into multiple cell types, including mature motor
neurons which are normally inaccessible for in vitro studies
(Veyrat-Durebex et al., 2014).
In fact, humanmotor neurons have been previously generated
from human embryonic stem cells and hiPSCs carrying specific
gene mutations, all related to the less prevalent, familial form
of ALS (Di Giorgio et al., 2008; Marchetto et al., 2008; Mitne-
Neto et al., 2011). Despite the substantial effort involved in
generating iPSC-derived, differentiated neurons from familial
ALS patients, such motor neurons developed from adult cells
(i.e., skin fibroblasts and erythroblasts) harbor specific gene
mutations, and thus may not represent an appropriate model
from which to develop translational therapies specific to the
more dominant, sporadic forms of ALS. Thus, this approach is
presently restricted to the less prevalent form of ALS (Leblond
et al., 2014).
In this study, hiPSC-derived motor neurons were obtained
from sporadic ALS patients by reprogramming motor nerve-
derived fibroblasts using a STEMCCACre-Excisable Constitutive
Polycistronic Lentivirus System containing the four transcription
factors OCT4, SOX2, KLF4, and CMYC (Somers et al., 2010).
A large gene profiling analyses of these differentiated motor
neurons was performed using a high-density oligonucleotide
microarray linked to specific tools capable of identifying
biological processes, molecular functions and pathways
deregulated in the sporadic ALS form.
Our results demonstrate that the generation of hiPSCs by
reprogramming motor nerve-derived fibroblasts from sporadic
ALS patients, followed by their differentiation into adult motor
neurons, is not only feasible, but more importantly, can be used
to model key molecular mechanisms which may recapitulate
those processes related to neurodegeneration in this disease state.
This approach may thus provide one of the most promising
platforms for the development of therapeutic targets specific to
sporadic ALS.
Methods
Human Tissue Samples
Sporadic ALS patients accompanied at the ALS Ambulatory Unit
of Department of Neurology of Clinics Hospital of University
of São Paulo School of Medicine signed informed consent
and were included in the present study after neurological
evaluation. Inclusion criteria were less than 6 months of
disease evolution after diagnosis according to EL ESCORIAL
(Brooks et al., 2000) and motor impairments not affecting
substantially one of the lower limbs. Sporadic ALS patients
showed preserved movements of the ankle and big toe in the
foot corresponding to the site of biopsy. Exclusion criteria
were the presence of associated pathologies, breathing disorders,
swallowing and cognitive disorders. Patients were submitted
to surgical procedures in one of their feet by means of local
anesthesia to collect a fragment of their extensor hallucis brevis
nerve which is a motor nerve that innervates the extensor hallucis
brevis muscle in the dorsal region of the foot. As control, biopsies
were taken from the distal accessory nerve performed during
reconstructive surgery of traumatic brachial plexus injuries of
non-ALS patients at the Clinics Hospital of University of São
Paulo School of Medicine. Non-ALS patients reported no history
of familial ALS and clinical evaluation failed to show any signs of
ALS. Both procedures were performed in the Surgical Center of
Functional Neurosurgery of Clinics Hospital of University of São
Paulo in accordance with protocol number 0187/11 approved by
the Ethics Committee for Analysis of Research Projects of Clinics
Hospital of University of São Paulo School of Medicine.
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DNA Sequencing to Exclude Most Frequent Gene
Mutations Associated with Familial ALS
SOD1 and TARDBP Analyses
The SOD1 and TARDBP genes were sequenced in ALS patients
to verify the absence of DNA mutations in genes normally
associated with familial ALS, thus providing further confirmation
of the sporadic form of ALS in patients included in the
study. Genomic DNA was extracted from peripheral blood
using standard methods. For sequencing analysis, primers were
designed so that they flanked all five exons of SOD1 and
the first six exons of TARDBP, both within intronic regions
(Hallewell et al., 1986; Xiong et al., 2010). Direct sequencing
of amplified exons was performed using Big-dye R© Terminator
v3.1 sequencing (Applied Biosystems, USA). Reactions were
performed by means of a ABI 3130 genetic analyzer (Applied
Biosystems), and sequences were analyzed by using a Mutation
Surveyor v5.0 (SoftGenetics, USA).
C9orf72 Repeat Expansions Analysis
Genomic DNA was isolated from peripheral blood according
to standard protocols. The repeat number of the GGGGCC
hexanucleotides was determined using genotyping primers.
Repeat-primed polymerase chain reaction (PCR) was performed
in order to provide a qualitative assessment of the presence of
C9orf72 repeat expansions, as previously described (Dejesus-
Hernandez et al., 2011). Briefly, 200 ng of genomic DNA were
used as template in a final volume of 28µl containing 12.5µl of
FastStart PCR Master Mix (Roche Applied Science, USA), and
a final concentration of 0.25mM 7-deaza-dGTP (Roche Applied
Science), 5% dimetil sulfoxide (Sigma-Aldrich, USA), 1M betaine
(Sigma-Aldrich) and 1µM of each primer. Sample analyses
were performed on an ABI 3500 genetic analyzer (Applied
Biosystems), and data evaluated using the GeneMapper software.
Repeat expansions are known to produce a characteristic
sawtooth pattern with a 6-bp periodicity, as previously described
(Dejesus-Hernandez et al., 2011).
hiPS Cell Generation
Fibroblasts were obtained from fragments of extensor hallucis
brevis peripheral motor nerve biopsies from sporadic ALS
patients and from distal accessory nerves collected from control
non-ALS patients. Fibroblasts of sporadic ALS and non-ALS
subjects were submitted to Sendai and STEMCCA methods of
reprogramming as described below.
Sendai Reprogramming
After purification, fibroblasts were expanded in culture (Seluanov
et al., 2010) and reprogrammed based on the protocol described
by Macarthur et al. (2012). Briefly, approximately 105 human
fibroblasts were seeded per well in a 6-well plate and incubated
at 37◦C and 5% CO2. The next day, cells were transduced
with the CytoTune iPS Reprogramming Kit containing Sendai
virus vectors (Life Technologies, USA; Cat. # A1378001) in
a fibroblast growth medium at a multiplicity of infection of
3, as described in the manufacturer’s protocols. The medium
was replaced with fresh fibroblast growth medium 1 day after
transduction and the cells were cultured for 7 days. Cells
(2 × 105 cells per dish) were cultured on an inactivated
mouse fibroblast feeder layer in 100mm tissue culture dishes
at day 8 of transduction. After an overnight period, the hiPSC
medium was replaced daily. The hiPSC medium is composed
of DMEM-F12 containing 20% knockout serum replacement
(KSR), 1% MEM non-essential amino acids (NEAA) solution,
0.1% 2-mercaptoethanol. Medium was equilibrated at 37◦C and
added with 4 ng/mL FGF-2 just prior the use. Reagents were
purchased from Life Technologies. The hiPSC colonies were
picked for expansion and characterization from days 27 to 30 of
reprogramming.
STEMCCA Reprogramming
Fibroblasts of sporadic ALS and non-ALS subject groups were
expanded in culture as described above. The reprogramming
was performed based on the protocol described by Somers
et al. (2010). Briefly, 105 fibroblasts were plated onto a
GelTrex (Life technologies) pretreated P35mm dish in 10%
fetal bovine serum and DMEM. The fibroblasts were subjected
to reprogramming 24 h after plating by STEMCCA Cre-
Excisable Constitutive Polycistronic Lentivirus (Millipore, USA)
expressing the pluripotency related genes OCT4, SOX2, KLF4,
and CMYC. DMEM media was replaced by E6 medium (Life
Technologies) supplemented with 10 ng/ml human FGF-2 (Life
Technologies) (E6F) and 0.5mMNaB (Sigma-Aldrich) 24 h after
transduction. The medium was changed by fresh E6F on days 3,
5, 7, and 9. Subsequently, the medium was changed daily from
day 11 to 25 by the E8medium (Life Technologies) supplemented
with 0.25mM of NaB (Sigma-Aldrich). The colonies were
visualized with the aid of a phase contrast microscope at the end
of that period and were collected manually. The colonies were
then seeded in GelTrex pretreated dishes for the expansion in E8
medium. The hiPSCs-derived from sporadic ALS and non-ALS
subjects were characterized by means of immunocytochemistry
(Table 1), reverse transcriptase polymerase chain reaction (RT-
PCR) and quantitative polymerase chain reaction (qPCR)
(Table 2) and alkaline phosphatase live stain described below.
Alkaline Phosphatase Live Staining
The culture media of hiPSCs from ALS and non-ALS
subjects achieved with Sendai and STEMCCA methods of
reprogramming were aspirated from colonies and were washed
twice with DMEM/F-12 medium (Gibco). The colonies were
incubated for 30min at 37◦C with alkaline phosphatase live
stain (Life Technologies) diluted in DMEM/F-12medium (1:500)
and then washed 3x with the same medium. Positive stained
colonies were visualized by means a FITC filter under fluorescent
microscopy (EVOS XL Core Imaging System, Life Technologies).
Karyotyping
Eighty percent confluent hiPSC colonies were incubated for 2 h
in the E8 medium with 0.5µg/ml colchicine for karyotyping
procedures. Cells were then harvested with TrypLE (Life
Technologies) and incubated for 20min at 37◦C in 0.075M KCl
solution, fixed in methanol/acetic acid (3:1), placed on pre-wet
chilled microscope slides, air-dried, and incubated for 2 days at
37◦C. The microscope slides were stained for 90 s with Wright’s
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TABLE 1 | Antibodies for characterization of hiPSC, embryoid body, differentiated motor neurons and cardiomyocytes.
Antibody Isotype Source Cat. No. Dilution
CHARACTERIZATION OF hiPSC
SSEA-4 Mouse IgG Life Technologies 414000 1:100
TRA1-60 Mouse IgG Life Technologies 411000 1:100
TRA1-81 Mouse IgG Life Technologies 411100 1:100
Oct4 Rabbit IgG Life Technologies A13998 1:100
EMBRYOID BODY DIFFERENTIATION IN VITRO
Pck-26 Mouse IgG Abcam ab6401-100 1:100
Myosin LC 2 Rabbit IgG Abcam ab79935-100 1:100
EphA2 Rabbit IgG Santa Cruz Biotechnology sc-924 1:100
DIFFERENTIATED MOTOR NEURONS
MAP2 Rabbit IgG Sigma-Aldrich M3696 1:100
ChAT Goat IgG Abcam Ab101755 1:100
DIFFERENTIATED CARDIOMYOCYTES
cTnT Goat IgG HyTest 4T19 1:200
CD-31 Mouse IgG1 BD Pharmingen 550389 1:100
TRA-1 Mouse IgM Merck Millipore MAB4360 1:300
Myo Mouse IgG1 Abcam Ab15 1:100
SSEA-4 (stage-specific embryonic antigen-4), TRA1-60 and TRA1-81 (podocalyxin-like), Oct-4 (octamer-binding transcription factor 4), Pck-26 (pan cytokeratin 26), Myosin LC 2 (myosin
light chain 2), EphA2 (ephrin type-A receptor 2), MAP2 (microtubule-associated protein 2), ChAT (choline acetyltransferase), cTnT (troponin T), CD-31 (cluster of differentiation 31), TRA-1
(histone acetyltransferase TRA1), Myo (Myosin). hiPSC were obtained from motor nerve fibroblasts of sporadic ALS and non-ALS subjects.
TABLE 2 | RT-PCR and qPCR primers for hiPSC and differentiated motor neuron gene markers.
Gene Forward 5′–3′ Reverse 5′–3′ pb
hiPSC CHARACTERIZATION
OCT4 GACAGGGGGAGGGGAGGAGCTAGG CTTCCCTCCAACCAGTTGCCCCAAAC 144
SOX2 GGGAAATGGGAGGGGTGCAAAAGAGG TTGCGTGAGTGTGGATGGGATTGGTG 151
NANOG CAGCCCTGATTCTTCCACCAGTCCC TGGAAGGTTCCCAGTCGGGTTCACC 343
GDF3 CTTATGCTACGTAAAGGAGCTGGG GTGCCAACCCAGGTCCCGGAAGTT 631
ESG/DPPA5 ATATCCCGCCGTGGGTGAAAGTTC ACTCAGCCATGGACTGGAGCATCC 243
DPPA4 GGAGCCGCCTGCCCTGGAAAATTC TTTTTCCTGATATTCTATTCCCAT 408
DPPA2 CCGTCCCCGCAATCTCCTTCCATC ATGATGCCAACATGGCTCCCGGTG 606
REX1/ ZFP42 AAAGCATCTCCTCATTCATGGT TGGGCTTTCAGGTTATTTGACT 267
DIFFERENTIATED MOTOR NEURONS
PAX6 GCCCTCACAAACACCTACAG TCATAACTCCGCCCATTCAC 149
OLIG2 AGCTCCTCAAATCGCATCC AAAAGGTCATCGGGCTCTG 380
CHAT TGAGTACTGGCTGAATGACATG AGTACACCAGAGATGAGGCT 144
HB9 GCACCAGTTCAAGCTCAAC GCTGCGTTTCCATTTCATCC 127
GAPDH ACATCGCTCAGACACCATG TGTAGTTGAGGTCAATGAAGGG 143
POUF51 (pou domain class 5, transcription factor), SOX2 (sex determining region Y-box 2), NANOG (homeobox transcription factor nanog), GDF3 (growth differentiation factor-
3), ESG/DPPA5 (embryonic stem cell specific gene/developmental pluripotency-associated), DPPA4 (developmental pluripotency-associated protein 4), DPPA2 (developmental
pluripotency-associated protein 2), REX1/ZFP42 (reduced expression protein 1/zinc finger protein 42), PAX6 (paired box 6), OLIG2 (oligodendrocyte lineage transcription factor 2),
CHAT (choline acetyltransferase), HB9 (homeobox 9) and GAPDH (glyceraldehyde-3-phosphate dehydrogenase). hiPSC were obtained from motor nerve fibroblasts of sporadic ALS
and non-ALS subjects.
stain in 2x buffer. Standard G-banding chromosome analysis
was performed by Clinics Hospital Molecular Diagnostic Services
(São Paulo, Brazil).
hiPSC Differentiation In vitro and
Characterization
Differentiation of induced pluripotent cells was accomplished as
described elsewhere (Evans and Kaufman, 1981; Martin, 1981).
Embryoid Body Differentiation
Briefly, hiPSCs were lifted using StemPro EZPassage (Life
Technologies) and maintained for 4 days in suspension for
embryoid body formation. The cells were cultured in embryoid
body medium, composed of knockout DMEM/F12 (Life
Technologies), supplemented with 20% KSR (Life Technologies),
2mM GlutaMAX (Life Technologies), 100µM NEAA (Life
Technologies), 1% antibiotic-antimycotic (Sigma-Aldrich) and
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100µM 2-mercaptoethanol (Life Technologies). Addition of
ROCK-inhibitor Y-27632 (Ascent Scientific, UK) for the first
24 h was used to improve the survival of hiPSC single cells (Lai
et al., 2010) and to allow an adequate generation of embryoid
bodies as well. The embryoid bodies were transferred to Geltrex-
coated tissue-treated dishes to allow cell attachment and were
maintained there for 1 week until their in vitro analysis of
differentiation by means of immunocytochemistry with specific
markers of three germ layers (Table 1).
Cardiomyocyte Differentiation
To further analyze their differentiation potential in vitro, hiPSCs
were induced to directly differentiate into cardiomyocytes.
The procedure was performed using a PSC cardiomyocyte
differentiation Kit (Life Technologies), according to the
manufacturer’s protocol. Briefly, after splitting, cells were fed
by cardiomyocyte differentiation medium A at day 4. Cells
were then fed by cardiomyocyte differentiation medium B on
day 6 and were maintained in a cardiomyocyte maintenance
medium from day 8 to day 14. At that time point, cells were
evaluated for their ability to show contraction as a normal
feature of cardiomyocytes (Supplementary Video), characterized
by immunocytochemistry for cardiomyocyte cell markers
(Table 1) and, stained with fluorescent phalloidin actin binding
(Life Technologies) performed according to the manufacture
instructions.
hiPSC Differentiation In vivo
In order to evaluate the ability of hiPSC to develop teratomas,
approximately 3x106 hiPSCs from ALS and non-ALS patients
were injected subcutaneously into the dorsal flanks of nude rats
anesthetized with ketamin (Cristália, Brazil)-xilazin (Vetbrands,
Brazil; 62.5mg/kg). Teratomas were allowed to expand for
about 6 weeks. They were visualized and dissected by means
of surgical procedure, fixed overnight in 4% paraformaldehyde
and transferred to 70% ethanol until they were embedded in
paraffin. Sections were stained with hematoxylin and eosin for
microscopy analyses. Protocols for animal use were previously
approved by the School of Medicine of the University of São
Paulo Institutional Animal Care and Use Committee.
Motor Neuron Differentiation and
Characterization
Motor neuron differentiation was performed according to a
protocol described by Hu and Zhang (2009) and modified
in our lab. Briefly, after reaching confluence, hiPSC colonies
were cultured in suspension in the presence of embryoid
body medium to achieve embryoid body formation as
described above. The medium was replaced on day 4 by a
neural differentiation medium containing DMEM/F12 (Life
Technologies), N2-supplement (Invitrogen, USA), 100µM
NEAA (Life Technologies), 1% antibiotic-antimycotic (Sigma-
Aldrich) and 2µg/ml heparin (Cristália) to induce the formation
of the neural progenitor cells. Clusters attached to laminin-
coated dishes (20µg/ml, Sigma-Aldrich) after 1 week in
suspension. Primitive neuroepithelial cells were posteriorized
by addition of 0.1µM retinoic acid (Sigma-Aldrich) at day 10
and ventralizated by the addition of 100 ng/ml sonic hedgehog
(Shh; Sigma-Aldrich) and B27 supplement (Gibco, USA) at
day 14. The cells were collected at differentiation day 20 for
microarray experiments. Samples of hiPSC-derived motor
neurons from ALS and non-ALS subjects were also obtained on
small laminin-coated coverslips (13mm) and characterized by
immunocytochemistry (Table 1), RT-PCR, qPCR (Table 2) and
Hb9::GFP live reporter.
Hb9::GFP Live Reporter Technique for Motor Neuron
Visualization
The construct containing Hb9-GFP (Hb9::GFP) reporter was
transferred to the differentiated motor neurons using a lentivirus
system (Marchetto et al., 2008). Hb9 is a motor neuron-specific
transcription factor expressed in mature cells that binds to the
promoter region of the green fluorescent protein (GFP) sequence
in the construct. HEK 293T cells were employed for virus
production. Briefly, triple transfection with calcium phosphate
was performed 24 h after plating using the PSPAX2 plasmids,
the pCMV-VSVg and the pLenti-Hb9-GFP (Addgene plasmid #
37080) or pEGIP (constitutive lentiviral vector for expression
of GFP; Addgene plasmid # 26777) (Marchetto et al., 2008;
Zou et al., 2009). The supernatant containing viral particles was
collected 24 and 48 h after transfection. In parallel, differentiated
motor neurons were plated at a concentration of 2 × 106
cells per dish on 60mm plates. Transduction was achieved by
adding the lentivirus to hiPSC-derivedmotor neuron cell cultures
after the treatment with Shh. The differentiated motor neurons
were maintained on small glass coverslips in 24-well plates
and transduced using 200µl viral supernatant plus 100µl of
neural differentiation medium containing 8mg/ml polybrene.
The medium was replaced 6 h after incubation at 37◦C and
5% CO2. The cells were fixed 72 h after transduction and
were evaluated for GFP expression using an Olympus AX-70
microscope (Olympus, JP).
Quantification of Differentiated Motor Neurons
The amount of differentiated motor neurons was quantified
by the counting of ChAT immunoreactive profiles and also
Hb9::GFP profiles counterstained with nuclear DAPI. Briefly, a
sample of cells were seeded onto small laminin-coated (Sigma)
glass coverslips and immunostained for ChAT (Millipore) or
labeled with Hb9:GFP methodology (the construct Hb9::GFP as
described above) followed by a DAPI nuclear labeling in order
to determine the number of differentiated motor neurons in the
sample fields. Evaluation of motor neuron vitality was performed
by means of Fluoro-Jade C (FJC) analysis as described in the
Figures S4E,F of the Supplementary Material (Schmued et al.,
1997, 2005).
Immunocytochemical Characterization
The hiPSC colonies, the embryoid body differentiation in vitro
and the differentiated motor neurons were characterized by
indirect immunofluorescence, as described elsewhere (Maximino
et al., 2014). Briefly, cells were fixed with 4% paraformaldehyde
and incubated with primary antibodies shown in Table 1.
Primary antibodies were detected using Alexa Fluor R© 488
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or 594-conjugated secondary antibodies specific for mouse,
rabbit and goat (all from Invitrogen). Preparations were
mounted on microscope slides and counterstained with nuclear
4′,6-diamidino-2-phenylindole dihydrochloride (DAPI; Vector,
USA). Digital images of immunofluorescence staining were
obtained bymeans of anOlympus AX-70microscope (Olympus).
RT-PCR and qPCR Characterization
Molecular characterizations of hiPSC and of differentiated motor
neurons of the chamber culture were performed by means of
RT-PCR and qPCR as described elsewhere (Maximino et al.,
2014). Briefly, total RNA of cells contained in the 24-well
plates was extracted using Trizol (Life Technologies) according
to the manufacturer’s protocol. The quantity (NanoDrop
1000 Spectrophotometer; Thermo Scientific, USA) and quality
(Agilent 2100 bioanalyser, RNA 6000 Pico LabChip; Agilent
Technologies, USA) of RNA were determined. cDNAs were
amplified by PCR using the primers specific for hiPSC and
differentiated motor neurons (Table 2). PCR products were
submitted to electrophoresis in 2% agarosis gels containing
ethidium bromide for 60min at 100 volts, and then visualized
under ultraviolet light exposure. qPCR reactions were performed
as described below. hESC (Fraga et al., 2011) and neural
progenitor cells were used as positive controls for hiPSC and
negative controls for motor neuron characterization, respectively
(Marti et al., 2013; Jha et al., 2015).
RNA Isolation and Microarray Experiments
The differentiated motor neurons that were achieved from a
pool of neuronal progenitor lines of the two sporadic ALS and
two non-ALS patients, this process were performed in three
different times. A total of three ALS and three non-ALS (control)
samples of differentiated motor neurons obtained were subjected
to large gene profiling by means of microarray analysis. The
same sampling procedure was employed in other quantification
methods of the study. The procedures of RNA isolation and
the methodology of microarray experiments were described in
our previous publication (Maximino et al., 2014). Briefly, total
RNA was extracted from differentiated motor neurons and linear
amplification of RNA was performed using the RiboampHSplus
kit (Arcturus) according to the manufacturer’s protocol, control
of RNA quality was them assessed, as described above. A
representative electropherogram from a Bioanalyzer evaluation
of RNA integrity of the differentiated motor neurons is shown
in the Supplementary Material (Figure S4H). RNAs of samples
(25 ng) and reference (100 ng) were reverse transcribed by the
low-input RNA linear amplification kit and then transcribed
to Cy5-labeled (samples) or Cy3-labeled (reference) according
to the manufacturer’s instructions (Agilent Technologies) and
to our previous descriptions (de Oliveira et al., 2013). A total
of 300 ng of Cy5-labeled cRNA was hybridized together with
the same amount of Cy3-labeled reference to Whole Human
Genome Oligo 8 × 60 K. All steps were performed according
to the manufacturer’s instructions (Agilent Technologies) and
to our previous descriptions (de Oliveira et al., 2013; Maximino
et al., 2014).
Microarray Analysis
The slide were scanned by a Microarray Scanner (Agilent) and
the raw image data were converted to numerical data using the
Agilent Feature Extraction Software, version 11.0.1.1 (Agilent
Technologies), as described in our previous study (Maximino
et al., 2014). Microarray raw data (.txt files) were imported into
GeneSpring v.13 GX software package (Agilent Technologies).
Raw signal intensities were normalized using this software. The
probes were tested for differential expression using a moderated
t-test for the comparisons between differentiated motor neurons
that were achieved from a pool of neuronal progenitor lines of the
two control patients and the two ALS patients, using GeneSpring
v.13 GX Software. Genes with p < 0.05 were accepted as
differentially expressed genes. The raw data from hybridizations
are available on the Gene Expression Omnibus Database, and the
GEO accession number is GSE68240. The data were registered in
the GEO according to the following description: control samples
(control sample 1, control sample 2, control sample 3) and
ALS samples (ALS sample 1, ALS sample 2, ALS sample 3) of
differentiated motor neurons that were achieved from a pool of
neuronal progenitor lines of the two control patients and the two
ALS patients, respectively.
Functional Enrichment Analysis
The functional annotation analysis of differentially transcribed
genes was performed using the Database for Annotation,
Visualization and Integrated Discovery (DAVID) web-server
v.6.7 (http://david.abcc.ncifcrf.gov) (Huang Da et al., 2009).
Gene Ontology (GO) terms of Biological Process and Molecular
Functions, and also Kyoto Encyclopedia of Genes and Genomes
(KEGG) pathways included in the DAVID knowledgebase
were considered. We have also focused on the GO terms
mitochondrion of the Cellular Component and their related
genes. Furthermore, the mean of gene expression normalized
signals related to the mitochondrion was compared between
the two groups. GO terms were submitted to REVIGO, a web
server that takes long lists of GO terms and summarizes them
in categories and clusters of differentially expressed genes by
removing redundant entries (Supek et al., 2011). The analysis
was conducted on the list containing the up-regulated and down-
regulated genes. High stringency (EASE score) parameters were
selected to improve confidence in those values designated as
enriched (Ashburner et al., 2000; Kanehisa et al., 2006).
Quantitative PCR
qPCR was carried out for the analysis the expression of
pluripotency markers, NANOG, SOX2, OCT4, and CHAT in
the hiPSCs and also the expression of the PAX6 (neural
stem cell marker), OLIG2 (motor neuron precursor marker),
and the CHAT, HB9 (mature motor neuron markers) in the
differentiated motor neurons. The details of the normalization
procedures were described in the legends of the Figures 2, 5
and Figure S4. Furthermore, a sample of differentially expressed
genes described by microarray was selected for verification by
qPCR, as described in our previous publication (de Oliveira
et al., 2014). The genes were chosen for verification based
on their high or low fold relative expression levels and
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possible involvement in ALS or other neurodegeneration related
mechanisms. Thus, dual specificity phosphatase 6 (DUSP6),
diacylglycerol o-acyltransferase 1 (DGAT1), potassium channel,
subfamily K, member 12 (KCNK12), kinesin family member
C1 (KIFC1); keratin associated protein 4-11 (KRTAP4-11);
leucine zipper-EF-hand containing transmembrane protein 1
(LETM1); succinate dehydrogenase complex assembly factor
1 (SDHAF1); caspase 9, apoptosis-related cysteine peptidase
(CASP9); vacuolar protein sorting 35 homolog (S. cerevisiae)
(VPS35); and insulin-like growth factor 2 (IGF2) were verified
by qPCR.
Briefly, cDNA of differentiated motor neurons, as
described above was synthesized from 50 ng of total RNA
by using a Maxima First Strand cDNA Synthesis Kit
(ThermoScientific,USA) according to manufacturer. qPCR
reactions were carried out in duplicate with 5 ng cDNA, the
DyNAmo Color Flash SYBR Green qPCR kit (Thermo Scientific)
and 400 nM of each primer in a final volume reaction of
20µl, by using the Applied Biosystems 750 Real-Time PCR
System (Applied Biosystems). The SYBR primers used in qPCR
verification can be found in Table 3.
The cycling in the SYBR reactions was composed of an initial
denaturation at 95◦C for 10min. Templates were subsequently
amplified by 40 cycles of 95◦C for 15 s and 60◦C for 30 s. A
dissociation curve was then generated to ensure amplification
of a single product, and the verification of no primer dimers
formation. A standard curve was generated for each primer
pair in order to determine the efficiency of the PCR reaction
over a range of template concentrations from 0.032 ng/µl to
20 ng/µl, using cDNA synthesized from human differentiated
motor neuron reference RNA. The efficiency for each set of
primers was 100 ± 5%. Gene expression was normalized to
GAPDH, and was determined using the 11Ct mathematical
model (ABI PRISM 7700 Sequence Detection System protocol;
Applied Biosystems). GAPDH was chosen as a housekeeping
gene to normalize the qPCR values because the microarray
analysis showed that its expression was stable across samples.
Statistical Analyses
The statistical method employed in the microarray analysis
is described above. The One-Way ANOVA was applied with
Tukey’s multiple comparisons post-test to identify statistical
significances between samples within groups. Furthermore, one-
tailed unpaired t-test was used to determine the statistical
significance of differences in qPCR experiments. All analyses
were performed using Graphpad Prism 5 (GraphPad, USA). Data
were presented as means ± SEM and significance level was set at
p < 0.05.
Results
Clinical Evaluation of ALS Patients and DNA
Sequencing
Sporadic ALS patients showed clinical and laboratory features
of ALS according to EL SCORIAL (Table 4). The evolution of
the disease did not exceed 29 months after initial symptoms
and ALS patients showed preserved movements of the ankle and
the big toe in the foot corresponding to the site of biopsy. The
amplitude of the big toemovement diminished after the biopsy of
the extensor hallucis brevis nerve, but they showed a progressive
recovery after 4 weeks of surgical intervention. Unfortunately,
due the natural evolution of the disease, ALS patients lost
movements of the entire inferior limbs in the subsequent months.
ALS patients did not present with any cognitive impairments or
familial history of neurodegenerative disease.
Non-ALS patients were adult subjects that had suffered
a unilateral injury of the brachial plexus months before the
procedure of plexus surgery. The distal fragments of the
preserved accessory nerve were obtained when the nerve was cut
and transferred to one of the major nerves of the brachial plexus.
That means the donor nerve was functional and did not show
signs of local inflammation at the time of surgery.
Sporadic ALS patients showed no SOD1 and TARDBP gene
mutations within the coding regions of those genes. Furthermore,
TABLE 3 | Primers used in SYBR qPCR verification of sporadic ALS motor neuron deregulated genes.
Gene Forward 5′–3′ Reverse 5′–3′ pb
DUSP6 ACAAGCAAATCCCCATCTCG CAGCCAAGCAATGTACCAAG 123
DGAT1 CAACTACCGTGGCATCCTG TTCTCCAGAAATAACCGGGC 72
KCNK12 CTTCTACTTCGTGGGCACC GCTCCAGGAAGAGGTTGAAG 143
KIFC1 TGGTAGTGCTAAGATGCTCATG ATCCGTCTTCACTTCCTGTTG 144
KRTAP4-11 CCCAACCTGTGTCATCTCC CTCCATGTGTCCTAATAGTCAGC 147
LETM1 CAAAGAGAAGGCAGAGAAGGAG GATGAGCCACTGAGAATCACC 137
SDHAF1 CGACAGTCCAAGGAACCC CCATGCAGTCAGGCGAG 127
CASP9 CCAACCCTAGAAAACCTTACCC TCTGCATTTCCCCTCAAACTC 149
VPS35 GTGGCAGATCTCTACGAACTTG TGGACTGAGGAAATGACTTGAC 106
IGF2 CCTGATTGCTCTACCCACC AACCTGATGGAAACGTCCG 150
GAPDH ACATCGCTCAGACACCATG TGTAGTTGAGGTCAATGAAGGG 143
DUSP6 (dual specificity phosphatase 6), DGAT1 (diacylglycerol o-acyltransferase 1), KCNK12 (potassium channel, subfamily K, member 12), KIFC1 (kinesin family member C1),
KRTAP4-11 (keratin associated protein 4–11), LETM1 (leucine zipper-EF-hand containing transmembrane protein 1), SDHAF1 (succinate dehydrogenase complex assembly factor 1),
CASP9 (caspase 9, apoptosis-related cysteine peptidase), VPS35 (vacuolar protein sorting 35 homolog), IGF2 (insulin-like growth factor 2) and GAPDH (Glyceraldehyde-3-Phosphate
Dehydrogenase). hiPSC were obtained from motor nerve fibroblasts of sporadic ALS and non-ALS subjects.
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TABLE 4 | Patient’s information.
ALS patients Control patients
Patient Sporadic ALS Sporadic ALS Non-ALS Non-ALS
Age 60 68 43 57
Gender Male Male Female Male
Biopsy date August 2013 August 2013 August 2013 August 2013
Date of onset March 2011 June 2011
Site of onset RLL LUL
Durationa (months) 29 26
ALS-FR scale in 2012 34/40 8/40
ALS-FR scale in 2014 30/40 34/40
Strength in the unilateral big toe 3/5 3/5
Electroneuromyography Chronic disease with anterior tip
cervico-thoraco-lumbar
Chronic disease with anterior tip
cervico-thoraco-lumbar and bulbar nucleus
Medicines Riluzole Riluzole, B vitamins and venlafaxin
Additional informations Depressive symptoms
RLL, right lower limb; LUL, left upper limb.
aTime from symptom onset to nerve biopsy. Patients from the ALS Ambulatory Unit of Department of Neurology were diagnosed accordingly to EL ESCORIAL and were submitted to
a biopsy of extensor hallucis brevis nerve. Non-ALS patients were followed at Neurosurgery Division of Department of Neurology and were submitted to a biopsy of motor branches of
accessory nerve during the reconstructive surgery of brachial plexus. The strength in the big toe of 3/5 indicates that functionality of segment was substantially preserved.
C9orf72 repeat expansions were not present in the sporadic ALS
patients (Figure S1).
Generation and Characterization of hiPSCs from
Motor Nerve Fibroblasts
Integration-free iPS cell lines were generated using a Sendai virus
-based on individual delivery of the 4 Yamanaka reprogramming
factors, i.e., OCT4, SOX2, KLF4, and CMYC (Takahashi
et al., 2007). Fibroblasts of all subjects showed successful
reprogramming, with no morphological changes observed up to
12 days of reprogramming. The colonies of stem cells were tightly
packed, showed a round morphology, and lacked well-defined
sharp edges (Figures S2A,B). Unfortunately, several colonies
regressed 3 weeks later and expansion of embryonic markers (see
below) occurred in only a few colonies. The emerging colonies
expressed the surface embryonic stem cell marker, SSEA4, and
the pluripotency marker, alkaline phosphatase as shown in
Supplementary Material (Figures S2C,D).
Based on the above results regarding the low level of
reprogramming achieved by the Sendai method in our
laboratory, we subsequently transduced fibroblasts using the
STEMCCA Cre-Excisable Constitutive Polycistronic Lentivirus
(Somers et al., 2010) in order to increase efficiency. In fact,
morphological changes were observed as early as 6 days after
reprogramming. Thus, 20 embryonic stem cell-like colonies
were picked and expanded under feeder-free conditions 4 weeks
after transduction. The best candidates for hiPSC clones from
sporadic ALS and non-ALS subjects were selected based on their
morphology and were employed in further characterization and
motor neuron differentiation experiments.
All hiPSC colonies obtained from sporadic ALS and non-
ALS control subjects showed classical morphology and their
cells expressed the surface embryonic stem cell markers SSEA-
4, TRA1-60, and TRA1-81, as well as the transcription factor
OCT4 (Figures 1A–F) and alkaline phosphatase (Figure 1G).
Karyotyping analysis of samples of hiPSC lines from all subjects
showed an absence of alterations in the hiPSC chromosomal
number and morphology (Figure 1H). Furthermore, colonies
from ALS and non-ALS subjects showed NANOG, SOX2,
OCT4, DPPA4, ESG/DPPA, DPPA2, REX1, GDF3, and CHAT
signals which were similar to those of an hESC line and
substantially different from the iPSC-differentiated motor
neurons (Figure 2A). Furthermore, hiPSC colonies obtained
from sporadic ALS and non-ALS control subjects expressed the
higher levels of NANOG and OCT4 as evidenced by the qPCR
experiments. Interestingly, the expression of SOX2, as seen in the
hiPSCs and also in the differentiated motor neurons could be
related to the fact that we have not performed the silencing of
exogenous factors after lentiviral induction or to a natural time-
dependent decrease of these pluripotency factors (Muratore et al.,
2014; Raitano et al., 2015) (Figure 2B).
The pluripotency of the hiPSCs from ALS and non-ALS
subjects was also evaluated in vitro through the formation of
embryoid bodies. All hiPSC lines differentiated spontaneously
into cell types of the three embryonic germ layers, as
indicated by expression of the specific markers; Pck-26
(ectoderm), Myosin LC 2 (mesoderm), and EphA2 (endoderm)
(Figures 3A–C).
Furthermore, the pluripotency of hiPSC from ALS and non-
ALS subjects was confirmed by the analysis of their ability to
develop teratomas in vivo, after subcutaneous injection in nude
rats. Histopathological analyses demonstrated tissues derived
from the three germ layers, including neural rosettes from
ectodermal origin, muscle tissue from mesodermal origin and
gut-like cells from endodermal origin (Figures 3D–F) in the
tumors 6 weeks after injection. These findings indicated a
successful reprogramming of fibroblasts to a pluripotent state
from sporadic ALS and non-ALS subjects.
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FIGURE 1 | Generation and characterization of STEMCCA transduced
hiPSC. Primary human induced pluripotent stem cells (hiPSC) colonies
derived from non-ALS (A) and ALS patients of sporadic form (B–H) after
transduction with STEMCCA Cre-Excisable Constitutive Polycistronic
Lentivirus expressing the embrionary genes OCT4, SOX2, KLF4, and CMYC
after several passages in E8 medium. hiPSCs were derived from fibroblasts of
extensor hallucis brevis nerve obtained by biopsy from sporadic ALS patients
and from distal fragments of the accessory nerve from a non-ALS subject.
Immunostaining of cultured hiPSC for SSEA-4 (B), TRA1-60 (E), TRA1-81
(C), and OCT-4 (F). The presence of OCT-4 immunoreactivity in the nucleus
of hiPSC samples that were not counterstained with nuclear DAPI is shown in
the box inside of the (F). Of note, OCT-4 has been described in cytoplasmic
vesicles (F), an event associated to regulation of pluripotency-associated
protein homeostasis of pluripotent cells (Cho et al., 2014; Muratore et al.,
2014). Cell nuclei were stained with DAPI (blue). hiPSC colonies were
analyzed for alkaline phosphatase activity using the Alkaline Phosphatase
Live Stain (G). Karyotyping sampling of hiPSC clone from an ALS patient, in
which metaphase plates showed the normal male chromosomal content (H;
42,XY). The same pattern was observed for other subjects of the study,
including the non-ALS patients (data not shown). Scale bars, 50µm.
Differentiation of hiPSC into Cardiomyocytes
hiPSCs were also differentiated into cardiomyocytes in order
to further characterize their potential to generate additional
mature cell types for further functional analyses. At 14
days, ALS differentiated cardiomyocytes were present as
spontaneously contracting syncytia (Supplementary Video)
expressing troponin T cardiac type 2 (cTnT) (Figures S3A,B),
but were negative for CD-31 (an endothelial cell marker; Figure
S3C), and TRA-1 (a stem cell marker, Figure S3D). hiPSC-
differentiated cardiomyocytes expressed positive double-staining
against myosin and actin to show the identity and the structural
pattern of cardiac differentiated cells (Figures S3E–H).
Differentiation of hiPSCs into Motor Neurons
hiPSC lines from ALS and non-ALS subjects were also
manipulated in order to generate mature motor neurons.
hiPSC colonies (Figure 4A) first generated embryoid bodies in
suspension (Figure 4B) and neuronal progenitor cells. Neural
progenitor cells expressing the PAX6 marker (Figure 5K) were
differentiated into post-mitotic motor neurons (Figures 4C,D)
expressing MAP2 (Figure 5A) and ChAT (Figure 5B). Motor
neurons were characterized further by means of a Hb9
(promoter/enhancer)-GFP (Hb9::GFP) reporter construct
(Figure 5C), an early marker of these maturing motor neurons.
Negative controls are shown in Figures 5D–F. There were no
differences in the neuronal differentiation process between
hiPSCs derived from sporadic ALS or non-ALS subjects. Samples
of differentiated hiPSC-mature motor neurons from ALS
patients (Figure 5G) and their non-ALS controls (Figure 5H)
showed axonal projections. The results of the quantification
of the number of differentiated motor neurons in the sample
regions of the coverslips revealed the presence of 95.39 and
95.3% of ChAT positive and Hb9 positive profiles, respectively,
in relation to the total amount of DAPI nuclear profiles in these
regions (Figures 5I,J).
RT-PCR and qPCR analyses of neuronal gene markers
of neural progenitor cells and differentiated motor neurons
contained in the 24-well plates are shown in the Figures 5K,L
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FIGURE 2 | Pluripotency markers of generated hiPSC. RT-PCR analysis
of pluripotency gene markers in human embryonic stem cells, in induced
pluripotent stem cells (iPSC) from motor nerve fibroblasts of an ALS patient
and in differentiated motor neurons after in vitro differentiation via embryoid
body protocol. The pluripotency gene markers, NANOG, SOX2, OCT4,
DPPA4, ESG/DPPA, DPPA2, REX1, GDF and also the gene choline
acetyltransferase (CHAT ), a marker of differentiated motor neurons were
employed (A). The expression of NANOG, SOX2, OCT4, and CHAT by qPCR
in the iPSC and differentiated motor neurons (Dif MN) was quantified and the
graph shows relative fold change values; a pool of the hESC was used as
reference samples with a reference value of 1 (B). iPSC and hESC show the
pluripotency gene markers and differentiated motor neurons show only the
CHAT marker (A,B). The hESCs were used as a reference parameter.
and Figure S4G of Supplementary Material. The marker PAX6
is present only in neural progenitor stage. Despite the very
low OLIG2 signal seen by RT-PCR (Figure 5K), a higher level
of signal amplification of OLIG2 was detected in differentiated
motor neurons by qPCR (Figure 5L and Figure S4G of
Supplementary Material). Furthermore, qPCR showed high
expressions of CHAT and HB9 in the differentiated motor
neurons compared to neural progenitor cells (Figure 5L and
Figure S4G). Of note, an absence of Fluoro-Jade C staining was
found in the 20 day-differentiated motor neurons, indicating that
age as an adequate period for molecular study in order to avoid
natural stress conditions of in vitro analysis.
Microarray Analysis
Microarray analysis demonstrated differentially expressed genes
in the hiPSC-derived motor neurons from sporadic ALS and
non-ALS subjects (Table S1). Statistical analyses have identified
1591 deregulated genes in differentiated motor neurons from
sporadic ALS compared to control subjects. Of these 1591 genes,
526 were up-regulated and 1065 down-regulated in sporadic ALS
compared to non-ALS subjects. The complete list of differentially
expressed genes can be found in Supplementary Table S1.
Gene Ontology Terms Grouped by REVIGO
Differentially expressed genes based on GO and grouped
by REVIGO could be characterized in clusters according
to molecular function, e.g., mRNA binding, GTP binding,
transcription (co)-repressor activities and low-density
lipoprotein particle receptor binding (Figure S5); as well
as gene clusters representing various biological processes
such as macromolecule catabolism, synapse organization,
aging, intracellular transport, negative regulation of DNA
binding, death, cell death, mitotic cell cycle and response
to inorganic substance (Figure S5). Detailed results for GO
terms regarding the GO numbers and number of genes as
well as the representative genes in each of these categories
can be found in Tables S2, S3 in Supplementary Material. The
Cellular Component indicated four GO term related with
mitochondrion, specifically the mitochondrion (105 genes),
mitochondrion part (65 genes), mitochondrion matrix (30
genes), and mitochondrion lumen (30 genes). The 105 genes of
mitochondrion GO term are overlapped with all other GO terms
(Table 5). The mean of gene expression normalized signal of
105 genes related to the mitochondrion of differentiated motor
neurons from sporadic ALS and non-ALS samples are shown
in Figure 6. Of note, the pattern of deregulated gene expression
was consistent among the 3 lines of differentiated motor neurons
of ALS and non-ALS groups, as exemplified by the absence
of statistical differences of the mitochondrion gene expression
within the each one of the two studied groups.
KEGG Analysis
Enriched KEGG terms were identified among differentially
expressed genes (p < 0.05) in hiPSC-derived motor neurons
of sporadic ALS and non-ALS subjects (Table 6). Importantly,
differentially expressed genes associated with Parkinson’s disease
and oxidative phosphorylation are present as over-represented
KEGG pathways. These pathways, and respective deregulated
genes associated with them, are seen in Table 6. The prostate
cancer pathway was omitted from the table because it was
composed of genes unrelated to ALS.
Verification of Microarray Results by qPCR
The results of qPCR for the 10 representative genes deregulated
in differentiated motor neurons from sporadic ALS compared
to non-ALS subjects are shown in Figure 7. Both the up
(SDHAF1; 4.88-fold; CASP9; 7.64-fold; VPS35; 8.59-fold and
IGF2; 13.52-fold) and down (DUSP6; –3.24-fold; DGAT1; –
1.23-fold; KCNK12; –2.97-fold; KIFC1; –1.07-fold; KRTAP4-11; –
2.46-fold; and LETM1; –3.03-fold) regulation observed for these
selected genes, as determined by qPCR, were coincident with and
supported our microarray results.
Discussion
Sporadic ALS is a complex disorder and patients present with
a wide range of diverse clinical outcomes regarding disease
Frontiers in Cellular Neuroscience | www.frontiersin.org 10 August 2015 | Volume 9 | Article 289
Alves et al. Differentiated motor neurons from sporadic ALS
FIGURE 3 | Spontaneous differentiation of hiPSC into three germ
layers in vitro and in vivo. Immunocytochemical staining of anti-Pan
cytokeratin (A; Pck-26, a marker of ectoderm layer), Myosin Light Chain (LC)
2 (B; a marker of mesoderm layer) and Ephrin A2 (C; a marker of endoderm
layer) after spontaneous differentiation in vitro of human-induced pluripotent
stem cells (hiPSC). hiPSC were derived from fibroblasts which were obtained
from motor nerve of sporadic ALS patient. Cell nuclei were stained with DAPI
(blue; A–C). Hematoxylin and eosin staining of sections from a teratoma
formed after a subcutaneous injection of hiPSC into nude rats (D–F). Neural
rosettes (arrow, D), muscle tissue (arrow; E), and gut-like epithelium (arrow,
F) indicate tissues into the teratomas with ectoderm, mesoderm and
endoderm features, respectively. Scale bars: 50µm.
onset, rate of progression and survival (Burkhardt et al., 2013).
High throughput gene expression analysis using microarrays
has not yet been described for iPSC-derived motor neurons
from sporadic ALS patients, thus contributing to a lack of
understanding of themechanisms underlying neurodegeneration
in this most common form of that human disease. The
absence of clear knowledge regarding the etiopathogenesis and
physiopathology of human sporadic ALS has been considered the
major cause for failure to translate potential therapeutic strategies
to the clinic. Indeed, most experimental studies resulting in
therapeutic targets rely fundamentally on experiments using
animal models carrying mutated genes of familial ALS (Beghi
et al., 2007; Musarò, 2010). Of note, the patients of this study
showed an early stage of ALS development, and the biopsy of the
motor nerve was performed in a still functioning limb segment,
thus the size of samples had to follow the roles of human ethical
research. Despite that limitation, the results demonstrated the
absence of internal variability.
Generation of hiPSC-derived Motor Neurons to
Study Molecular Mechanisms in Sporadic ALS
Peripheral motor nerves of ALS patients were used for the
first time to provide adult fibroblasts, in contrast to numerous
previous studies using skin fibroblasts (Almeida et al., 2013;
Zhang et al., 2013; Devlin et al., 2015), to be reprogrammed
to hiPSCs. Motor nerves, as a source of adult cells for
reprogramming, represent a logical choice with which to
model ALS particularly since retraction of motor axons and
denervation of the neuromuscular junction are the earliest
events in the disease (Fischer et al., 2004; Schaefer et al., 2005;
Pun et al., 2006). In fact, recent evidence describing neuronal
dye-back mechanisms, combined with our own unpublished
data, suggest that peripheral cells associated with motor axons,
such as Schwann cells, may play a role in motor neuron
degeneration in ALS (Keller et al., 2009; Maximino et al.,
2014), particularly in the sporadic form. Furthermore, previous
microarray studies also showed a differential pattern of gene
expression in peripheral fibroblasts from ALS patients (Raman
et al., 2015). These non-neuronal cells associated with peripheral
motor nerves may provide additional information related to the
pathogenic mechanisms of sporadic ALS once hiPSC-derived
motor neurons could be produced from them. Of note, the
growth and differentiation of peripheral motor nerve fibroblast-
derived hiPSCs shown in this work seemed to be comparable
to those hiPSCs derived from adult skin fibroblasts described
elsewhere (Chestkov et al., 2014).
In support of this approach, in the present study, we initially
generated integration-free iPS cell lines using Sendai virus -based
individual delivery of each of the four Yamanaka reprogramming
factors. However, a greater efficiency was achieved by using
STEMCCA Cre-Excisable Constitutive Polycistronic Lentivirus.
The combination of all factors in a single transcript using
STEMCCA technology may be responsible for the increased
efficiency of reprogramming (Awe et al., 2013; Kadari et al.,
2014). In our study, this may have allowed the efficient
production of hiPSCs from peripheral motor nerve fibroblasts
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FIGURE 4 | hiPSC-differentiated motor neurons. Human induced
pluripotent stem cells (hiPSC) sample obtained from motor nerve fibroblasts of
a sporadic ALS patient. hiPSC colony growing on feeder free medium forms
uniform colonies (A). The motor neuron progenitors are cultured in suspension
(embryoid bodies; B). Axonal lengths project from the clusters in an adherent
culture (C). The hiPSC-derived motor neurons are showing classical
morphology with axonal projections (D). Scale bars: 50µm.
and may have contributed to the subsequent success of motor
neuron differentiation. Moreover, as far as we know, it is the
first time that the STEMCCA methodology has been applied to
generate hiPSC-derived motor neurons.
The potential for motor neuron differentiation achieved by
means of the embryoid body method has been previously
discussed by Hu and Zhang (2009). The neuronal differentiation
process was initiated with the formation of cell aggregates in
suspension (free-floating spheres). Furthermore, the subsequent
stages involved in the acquisition of the precise motor neuron
identities established by the neural progenitor cells, in a process
that recapitulated those defined during normal mammalian
embryonic development (Dasen and Jessell, 2009). The first step
is the acquisition of a “spinal cord” character, i.e., caudalization,
by means of extrinsic signals, i.e., retinoic acid. The cell
specification along the dorsoventral axis, i.e., ventralization,
occurs in response to Shh signaling (Jessell, 2000; Li et al.,
2008). After that, differentiating neurons are maintained in the
culture medium supplemented with specific neurotrophic factors
to undergo further maturation, including the ability to produce
specific neurotransmitters and to show specific morphological
characteristics of adult motor neurons (Nizzardo et al., 2010).
Because our objective was to assess early changes in the gene
expression profile of differentiated motor neurons of sporadic
ALS patients, microarray analyses were performed on day 20 of
differentiation, a time point at which obtained motor neurons
already expressed the specific markers ChAT and Hb9. Of note,
we did not perform any electrophysiological tests related to
mature neuron function on our iPSC-derived motor neurons.
However, despite the OLIG2 expression shown by qPCR, the
majority of differentiated motor neurons showed ChAT and
also Hb9 markers at that culture age. Also, the cells possessed
morphology of mature cells at that time. Thus, the results of
CHAT and HB9 by qPCR together with high number of ChAT
and Hb9 positive cells in our differentiated motor neuron culture
conditions emphasize the state of early mature motor neurons
in our system. Furthermore, the expression of OLIG2 seen in
our system has been mentioned previously. In fact, expression
of progenitress markers can be encountered in different types of
transformed mature cells (Lian et al., 2012). The same should
be true for IPSC-derived mature motor neurons because the co-
expression of OLIG2, HB9, and CHAT were found at different
stages of maturation (Hester et al., 2011; Jha et al., 2015), a
process that may last for several weeks in culture. Nevertheless,
the persistent presence of OLIG2 expression in motor neurons
may not impair the differentiation process because generated
motor neurons over-expressing Olig2, which were generated
by a pLPCX-Olig2 retroviral transfection, were able to acquire
morphological, biochemical and electrophysiological properties
of mature cells (Lee et al., 2014). Nevertheless, it should be a
matter of a next investigation whether a non-excisable system,
as it is the case of the present study, may be responsible for the
presence of OLIG2 in the mature differentiated motor neurons.
Of note, despite the high number of differentiated motor
neurons found in the coverslip, that sample analysis should
not be taken as a parameter of reprograming/differentiation
efficiency, which was not the scope of the present paper. A
highly variable efficiency has been described in the literature,
which is due to several factors related to differences of the
protocols, iPSCs clones, substratum and also the limitation of the
methodology to evaluate the final results (Hu and Zhang, 2009;
Takazawa et al., 2012; Amoroso et al., 2013; Qu et al., 2014; Toli
et al., 2015). Our qPCR analysis on regulation of transcripts of
differentiated motor neuron markers may be a better method to
document the type of cultured cell RNA that was evaluated in the
microarray.
Furthermore, we decided to evaluate the gene profiling in the
20 day cultured ChAT and Hb9 expressed differentiated motor
neurons in order to minimize the stress condition of in vitro
assay and also because we were interested in the early molecular
changes in the disease that could be related to the triggering of
motor neuron death. Our decision to study molecular regulation
on early mature differentiated motor neurons was also based
on the fact that cultured motor neurons from ALS mouse start
showingmorphological alterations after 14 days in culture (Nagai
et al., 2007), the expression of the mature marker may decrease in
these cells from culture days 20–30 (Hester et al., 2011), and also
because human derived motor neurons could show molecular
instability in the process of maturation (Almeida et al., 2013).
Despite the early age of differentiatedmaturemotor neurons, that
time point seems to be a safer stage to study molecular feature of
the disease model in reprogrammed cells. Nevertheless, a detailed
analysis of molecular changes at different phases of motor neuron
maturation should be a matter of a future investigation.
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FIGURE 5 | Specific labeling and qPCR differentiation gene
markers of hiPSC-derived motor neurons. Sample of differentiated
human induced pluripotent stem cells (hiPSC)-mature motor neurons
are arranged in clusters and show axonal projections. Cells are positive
for MAP2 (A; green), ChAT (B; red) and express GFP under control
of motor neuron-specific gene Hb9 (C). The negative controls for each
motor neuron marker mentioned above are seen in (D–F), respectively,
and no specific labeling was found. Human induced pluripotent stem
cells (hiPSC)-differentiated mature motor neurons from ALS patients (G)
and their non-ALS controls (H) are arranged in clusters and show axonal
projections. Number of differentiated motor neurons was quantified by the
counting of ChAT+/DAPI profiles (I) and Hb9+/DAPI profiles (J) in sample
regions of the coverslips and the results are expressed as percentage of
total cells. Scale bars: 50µm. RT-PCR analysis of neuronal gene markers
of differentiated motor neurons and neural progenitor cells (K) contained in
the 24-well plates. The markers of PAX6 (neural progenitor stage), OLIG2
(motor neuron progenitor stage), CHAT (mature motor neuron stage)
and GAPDH (endogenous control gene) are evidenced. The expression
of PAX6, OLIG2, CHAT, and HB9 was quantified in differentiated
motor neurons contained in the 24-well plates by qPCR and the graphic
shows the relative fold-change values; a pool of the neural progenitor
cells was used as reference samples with a reference value of 1 (L).
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TABLE 5 | Genes from GO terms related to the cellular component mitochondrion.
ACAA2 C1QBP DUT JMJD7 MRPS18C NDUFV3 SLC25A15
ACAD9 CAV2 E2F1 LETM1 MRPS22 NLRX1 SLC25A32
ACAT1 CHCHD10 ELOVL6 LIAS MRPS6 OPA1 SLC25A44
ACOT9 CKMT1A FANCG LRRC59 MTIF3 PDHX SOD1
ACSM2B COX17 GFM1 LRRK2 MTRR PI4KB STAR
AK3 COX6A1 GFM2 LYRM4 MUL1 POLG STOML2
ALDH3A2 COX7C GLRX2 MACROD1 NAPG PPP2R1A SURF1
ALKBH3 CPOX GLS MCF2L ND2 PSMC4 TMEM143
ASAH2 CRAT GRN MMADHC NDUFA12 PTPN11 TMX4
ATP5B CTSB GRPEL1 MRPL17 NDUFA2 ROMO1 TOMM20L
ATP5C1 CYCS HSPD1 MRPL23 NDUFA4 SDHAF1 TOMM40
ATP5D DBT HTRA2 MRPL37 NDUFAF3 SDHC TSPO
ATP5E DIABLO IARS2 MRPL46 NDUFB5 SFXN4 VDAC1
ATPAF1 DNAJA3 IDH2 MRPL9 NDUFB6 SIRT3 VPS25
BZRAP1 DTD1 IFI6 MRPS14 NDUFC2 SIRT5 YWHAZ
The Cellular Components GO terms mitochondrion (0005739), mitochondrial part (0044429), mitochondrial matrix (0005759) and mitochondrial lumen (0031980) were composed by
105, 65, 30, and 30 genes, respectively. All genes of GO terms mitochondrion, mitochondrial part, mitochondrial matrix and mitochondrial lumen were also present in the GO term
mitochondrion.
FIGURE 6 | Mitochondrion gene expression in hiPSC-derived motor
neurons. Gene expression normalized signals of 105 genes from GO terms of
Cellular Components that are related to the mitochondrion. Bars represent the
means ± SEM of the signals from three samples of differentiated motor
neurons of non-ALS and ALS patients, as described in the text. The signal
values (Cy5) were normalized by microarray reference (Cy3). The genes
referred to GO terms mitochondrion (0005739), mitochondrial part (0044429),
mitochondrial matrix (0005759), and mitochondrial lumen (0031980). See text
and Table S4 for details. Differences within groups were analyzed by One-Way
ANOVA followed by Tukey post-test, whereas differences between non-ALS
and ALS groups were analyzed according to unpaired t-test **p < 0.01.
The adequacy of sporadic ALS-derived iPSC-differentiated
motor neurons for molecular studies is also highlighted by
our results of the large gene profiling analysis, which is in
line with profiles previously described using cells or tissues
from post-mortem human ALS subjects or from animal models
(Olsen et al., 2001; Dangond et al., 2004; Malaspina and De
Belleroche, 2004; Jiang et al., 2005; Perrin et al., 2005; Ferraiuolo
et al., 2007, 2011; Yamamoto et al., 2007; Offen et al., 2009;
Brockington et al., 2010; D’Arrigo et al., 2010; Guipponi et al.,
2010; Saris et al., 2013). Of note, we have not performed the
excision of inserted cassette in our hiPSC cell lines to avoid
an additional step of cell manipulation, what has not impaired
the differentiation of mature Hb9 expressing motor neurons.
There is a lack of detailed information regarding the presence
and effects of residual reprogramming transgene expression the
iPSCs-derived motor neurons. Based on the fact that residual
reprogramming transgene expression from integrated viruses
may alter the biological properties of iPSCs (Sommer et al., 2012),
future work should analyze the gene profiling in hiPSC-derived
motor neurons after silencing the exogenous factors. Despite
the novelty of the methodological approach, the results of the
present gene profiling in the differentiated motor neurons should
be taken into attention before in vivo experiments because it is
difficult to control all consequences of cell reprograming and also
to avoid the stress conditions of any in vitro studies.
Importantly, the present gene profiling analysis of iPSC-
derived motor neurons from sporadic ALS patients provides
evidence of possible novel and autonomous mechanisms
underlying neurodegeneration in the most abundant form of
human ALS. It should be emphasized that previous descriptions
on the regulation of gene expression in ALS are based solely on
studies with animal models or human post-mortem tissue.
GO Molecular Function and Biological Processes
from Sporadic ALS Motor Neuron Deregulated
Genes
The microarray analyses identified 1591 deregulated genes
in differentiated motor neurons from sporadic ALS patients
compared to control subjects. The differentially expressed genes
with a p-value lower than 0.05 were submitted to enrichment
analyses based on GO and KEGG databases, according to our
previous publications (de Oliveira et al., 2013; Maximino et al.,
2014). Differentially expressed genes based on GO and grouped
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TABLE 6 | KEGG pathways obtained from microarray analysis.
Gene ID Gene name Gene symbol Fold
PARKINSON’S DISEASE
842 Caspase 9, apoptosis-related cysteine peptidase CASP9 4.200
7416 Voltage-dependent anion channel 1 VDAC1 2.289
514 ATP synthase, H+ transporting, mitochondrial F1 complex, epsilon subunit ATP5E 2.184
1350 Cytochrome c oxidase subunit VIIc COX7C 1.928
509 ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 1 ATP5C1 1.887
513 ATP synthase, H+ transporting, mitochondrial F1 complex, delta subunit ATP5D 1.865
27429 HtrA serine peptidase 2 HTRA2 1.789
4712 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6, 17 kDa NDUFB6 1.684
54205 Cytochrome c, somatic CYCS 1.629
1337 Cytochrome c oxidase subunit VIa polypeptide 1 COX6A1 1.599
120892 Leucine-rich repeat kinase 2 LRRK2 −1.885
506 ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide ATP5B −2.076
4697 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4, 9 kDa NDUFA4 −2.093
4695 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 2, 8 kDa NDUFA2 −2.724
4718 NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 2, 14.5 kDa NDUFC2 −3.004
4731 NADH dehydrogenase (ubiquinone) flavoprotein 3, 10 kDa NDUFV3 −3.109
4536 MTND2 ND2 −3.302
7327 Ubiquitin-conjugating enzyme E2G 2 UBE2G2 −3.489
6391 Succinate dehydrogenase complex, subunit C, integral membrane protein, 15 kDa SDHC −7.239
4711 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 5, 16 kDa NDUFB5 −8.217
OXIDATIVE PHOSPHORYLATION
5464 Pyrophosphatase (inorganic) 1 PPA1 2.279
514 ATP synthase, H+ transporting, mitochondrial F1 complex, epsilon subunit ATP5E 2.184
1350 Cytochrome c oxidase subunit VIIc COX7C 1.928
509 ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 1 ATP5C1 1.887
513 ATP synthase, H+ transporting, mitochondrial F1 complex, delta subunit ATP5D 1.865
4712 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6, 17 kDa NDUFB6 1.684
1337 Cytochrome c oxidase subunit VIa polypeptide 1 COX6A1 1.599
496 ATPase, H+/K+ exchanging, beta polypeptide ATP4B −1.329
10063 COX17 cytochrome c oxidase copper chaperone COX17 −1.863
506 ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide ATP5B −2.076
4697 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4, 9 kDa NDUFA4 −2.093
4695 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 2, 8 kDa NDUFA2 −2.724
4718 NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 2, 14.5 kDa NDUFC2 −3.004
4731 NADH dehydrogenase (ubiquinone) flavoprotein 3, 10 kDa NDUFV3 −3.109
4536 MTND2 ND2 −3.302
51382 ATPase, H+ transporting, lysosomal 34 kDa, V1 subunit D ATP6V1D −3.729
6391 Succinate dehydrogenase complex, subunit C, integral membrane protein, 15 kDa SDHC −7.239
4711 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 5, 16 kDa NDUFB5 −8.217
Microarray analyses of hiPSC-derived motor neurons from sporadic ALS and non-ALS subjects. Positive and negative values correspond to up regulation and down regulation fold
changes, respectively. The significance of enrichment (EASE score) was considered p < 0.05. The Parkinson disease and oxidative phosphorylation pathways were obtained. The gene
names and symbols are seemed.
by REVIGO displayed molecular functions and biological
processes consistent with mechanisms potentially contributing
to the autonomous motor neuron cell death characteristic of
sporadic ALS.
A wide range of terms of GO molecular function and
biological processes grouped by REVIGO have already been
implicated in ALS etiopathology. Moreover, their wide ranging
and diverse activities underline the high degree of complexity
of molecular and biochemical events taking place in the
sporadic form of this disease. For instance, within the mRNA
binding cluster (Takanashi and Yamaguchi, 2014; Štalekar et al.,
2015), hnRNPA1, which codes for a heterogenous nuclear
ribonucleoprotein A1, was up-regulated, and has been related
to frontotemporal dementia and ALS (Seelen et al., 2014).
The GTP binding cluster was previously correlated with ALS
(Otomo et al., 2003; Droppelmann et al., 2014). However,
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FIGURE 7 | qPCR verification of deregulated genes. Graphs show relative
fold change values of down regulated (A) and up regulated (B) of selected genes
for verification in human-induced pluripotent stem cells (hiPSC)-differentiated
motor neurons from sporadic ALS and non-ALS subjects. hiPSC were obtained
from motor nerves of subjects. The selected genes were IGF2, VPS35, CASP9,
HFE, and SDHF1 (A) and also DUSP6, DGAT1, KCNK12, KIFC1, KRTAP4-11,
and LETM1 (B). A pool of the non-ALS group was used as reference samples
with a reference value of 1. See text for details. Means ± SEM at least 3
replicates for each group. *, ** and *** p-values indicate the <0.05, <0.01 and
<0.001 levels of significance, respectively, according to unpaired t-test.
the possible involvement of the down regulation of FKBP-
4 in the cell-autonomous neurodegeneration characteristic of
the sporadic form of ALS is an original contribution of this
study. Furthermore, the deregulated FKBP-4, which belongs to
the immunophilin chaperone protein family, may contribute
to anti-aggregation processes of proteins widely described in
ALS (Steiner et al., 1997; Gold et al., 1999; Manabe et al.,
2002). Of note, the transcription (co)-repressor activity cluster
(Tan et al., 2012; Dini Modigliani et al., 2014) revealed by
REVIGO, identified NKX2 as an up-regulated gene product.
NKX2 encodes a natural antisense RNA that modulates the
expression of sense transcripts and mRNA processing, and
might be involved in intracellular processes related to neuronal
degeneration in sporadic ALS (Werner and Sayer, 2009). The
synapse organization cluster (Shefner et al., 2006; Venkova et al.,
2014) contains up-regulated MAP1B, which encodes a molecule
linked to microtubule and synaptic stabilization and was found
altered in spinal cords from ALS patients (Coyne et al., 2014).
Perhaps most significantly, REVIGO analysis has revealed a
possible critical role for mitochondria in the diverse mechanisms
contributing to neurodegeneration in ALS. Of note, the synapse
organization cluster included the mitochondrion organization
category in which the strongly deregulated genes, LETM1 and
SDHF1, were identified (discussed below). Also, the intracellular
transport cluster (Alami et al., 2014; Foran et al., 2014) contains
the highly down-regulated gene, APOE, whose product is
involved inmitochondrial oxidative stress in ALS, and its variants
have been correlated to an increased risk of bulbar-onset of
human ALS (Praline et al., 2011). Furthermore, the intracellular
transport category also contains the significantly down-regulated
KIF1A and KIFC1 genes (also included in several GO terms)
whose protein products are responsible for anterograde axonal
transport of mitochondria (De Vos et al., 2008; Hou and Yang,
2013), a process that is altered in ALS (De Vos et al., 2008).
Additionally, the mitotic cell cycle cluster (Cova et al., 2010)
revealed an up-regulation of DCTN1, encoding the p150 subunit
of the axonal transport protein dynactin. Importantly, mutations
in this gene have been associated with sporadic and familial ALS
(Münch et al., 2004, 2005).
Significantly, REVIGO analysis provided direct evidence of
mitochondrial involvement in the autonomous mechanisms
underlying neurodegeneration in ALS with data associated
with the cell death and death clusters (Martin et al., 2000;
Tapia, 2014). These clusters contained the up-regulated gene,
ATXN10, which has previously been associated with ALS
(Figley et al., 2014), possibly involving mitochondria and
activation of caspase 3 (White et al., 2010). Interestingly,
the down-regulation of DYNLL1, also associated with this
cluster, may be associated with impairment of dynein induced
retrograde axonal transport of mitochondria in ALS (Chen et al.,
2010).
Admittedly, it is difficult to separate the initial triggering
from secondary events associated with stress of oncoming
neurodegeneration based solely on results of the GO analysis
of molecular function and biological process. Moreover, despite
a huge diversity of events revealed by GO analysis, the general
processes involving mitochondria may represent possible early
autonomous mechanisms associated with sporadic ALS motor
neurons. It should be stressed that mitochondrial functions also
appear in several terms associated with cellular components of
GO (data not shown).
KEGG Pathways from Sporadic ALS Motor
Neuron Deregulated Genes
The DAVID analysis identified two specific KEGG pathways
that might be related to ALS mechanisms of motor neuron
degeneration in sporadic ALS, the Parkinson’s disease and
oxidative phosphorylation pathways. ALS and Parkinson’s
disease share some features and mechanisms of neuronal
degeneration (Bosco et al., 2011; Shulman et al., 2011), thus
emphasizing the relevance of the present molecular analysis
employing human motor neurons. In fact, there is growing
evidence from work of the past two decades suggesting that
ALS may show a complex combination of events at both
molecular and cellular levels that are common to Parkinsonism
and frontotemporal dementia (Espay et al., 2011). For instance,
TARDBP mutations (Mosca et al., 2012), TDP-43 proteinopathy
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(Mackenzie et al., 2010) and C9orf72 expansion (Lagier-
Tourenne et al., 2013) are common to all three pathologies.
The oxidative phosphorylation pathway identified in the
KEEG analysis is consistent with mitochondrial participation
in sporadic ALS pathology (Ladd et al., 2014). For example,
impairments of mitochondrial bioenergetics and energy
metabolism, oxidative stress and apoptosis, among other features
have been previously described (Cassina et al., 2008; Hedlund
et al., 2010; Dupuis et al., 2011; Reddy et al., 2011; Cozzolino and
Carrì, 2012; Federico et al., 2012; Brockington et al., 2013; Heath
et al., 2013).
The importance of the above two KEEG pathways in
the autonomous mechanisms related to neurodegeneration in
sporadic ALS is highlighted by recent descriptions of the
involvement of their genes in the degeneration of motor neurons
in ALS and other neurodegenerative disorders related to ALS. For
instance, LRRK2 mutations are associated with Parkinsonism,
ALS and dementia (Wszolek et al., 1997; Zimprich et al.,
2004), leading to mitochondrial fragmentation, mitochondrial
dysfunction and increased reactive oxygen species (Whittle et al.,
2007; Wang et al., 2012). Thus, the down regulation of LRRK2 in
iPSC-derived motor neurons from sporadic ALS subjects in the
present study provides further confirmation of the importance of
mitochondrial dysfunction in this neurodegenerative disorder.
The down regulation of ATP5B we have identified in
differentiated motor neurons from sporadic ALS patients in the
present microarray analysis correlates with previous findings
of reduced cytochrome oxidase and ATP synthase activities
described in neurodegenerative disorders (Schägger and Ohm,
1995; Bosetti et al., 2002; Sergeant et al., 2003; Basso et al., 2004;
Pamplona et al., 2005). For example, ATP5B deregulation was
previously characterized in western Pacific ALS-parkinsonism-
dementia complex (Shiraki, 1975).
Mitochondrial involvement in the autonomous motor
neuron cell death in sporadic ALS is also supported by the
up-regulation of VDAC1 seen in the microarray analyses.
VDAC1 encodes for a voltage dependent anion channel
in the outer mitochondrial membrane, and thus is able to
regulate local ATP/ADP flux (Colombini, 2004; Lemasters
and Holmuhamedov, 2006). Interestingly, VDAC1 is also a
key player in mitochondria-mediated apoptosis and has been
implicated in apoptotic-relevant mitochondrial events (Shimizu
et al., 1999; Shoshan-Barmatz et al., 2006, 2008; Tajeddine et al.,
2008; Abu-Hamad et al., 2009; Arbel and Shoshan-Barmatz,
2010). Misfolded mutant SOD1 directly binds and inhibits
VDAC1 conductance, thus impacting the onset and survival in
the ALS mouse model (Israelson et al., 2010). Furthermore, the
deregulation of VDAC1 may also trigger neuronal damage by a
direct interference in the regulation of mitochondrial reactive
oxygen species (Liu et al., 2004; Vande Velde et al., 2004) or
by a direct activation of mitochondrial apoptotic pathways
(Tsujimoto and Shimizu, 2002; Shoshan-Barmatz et al., 2006;
Yagoda et al., 2007; Abu-Hamad et al., 2008).
Additional evidence in support of mitochondrial dysfunction
in autonomous sporadic ALS is provided by the demonstration
that significant up-regulation of HFE may be associated with
iron homeostasis. HFE mutations have been linked to human
ALS (Rothstein, 2009; Kwan et al., 2012) and changes in iron
metabolism may confer susceptibility to this disease in both
humans (Li et al., 2014) and animals (Nandar et al., 2014).
Because mitochondria regulate intracellular iron homeostasis
(Horowitz and Greenamyre, 2010), HFE deregulation may
represent an additional mitochondrial-based pathogenic
mechanism in sporadic ALS. Mitochondrial dysfunction leading
to cell autonomous neuronal damage in sporadic ALS is also
supported by the significant deregulation of both TOMM20L
(Ryan and Gogvadze, 1999) and HtrA2/Omi (Srinivasula et al.,
2003), as seen in our microarray analysis.
Finally, many of the genes identified as being dysregulated in
our microarray analysis have not yet been previously associated
with ALS in any context. However, some (eg. ATP5D, ATP5E,
NDUFA4, NDUFB5, NDUFB6) have been implicated in other
neurodegenerative disorders (Chen et al., 2014; Suszyn´ska-
Zajczyk et al., 2014). Additionally, NDUFC2, ND2, COX7C,
NDUFV3, SDHC, ATP5C1, COX6A1, ATP4B, ATP6V1D, and
COX17 are associated with mitochondrial function or impaired
bioenergetic metabolism, and thus further support a role for
mitochondrial dysfunction in the cell autonomous degeneration
of motor neurons in sporadic ALS (Burman et al., 2014).
GO Mitochondrion Genes of the Cellular
Component
Regulation of some of the mitochondrial genes and their related
proteins of the cellular component mitochondrion described in
the microarray analysis have been mentioned in the context of
neuronal degeneration and ALS. For instance, C1QBP, CAV2,
CTSB,DIABLO,GLRX2,NDUFA4,NLRX1,OPA1, SDHC, SIRT3,
SURF1 have been correlated to neuronal death and to excitotoxic
events (Manfredi and Beal, 2000; Weiergräber et al., 2007;
Hayashi et al., 2009; Bräutigam et al., 2011; Gray et al., 2013;
Tian et al., 2013; Imbeault et al., 2014). Some of them were
related to complex cellular mechanisms of neurodegenerative
disorders, also involving other cellular organelles as it is the
case of CTSB in lysosomal function (Sevenich et al., 2006;
Cho et al., 2013). Further indication of the importance of
mitochondrion gene regulation in the mechanisms of ALS is
highlighted with the descriptions of mitochondrial oxidative
stress leading SDHC mutation-induced apoptosis (Ishii et al.,
2011) and of neuroprotection after inhibition of mitochondrial
release of the pro-apoptotic protein Smac/DIABLO (Soustiel and
Larisch, 2010; Luan et al., 2012).
The genes ATP5B, E2F1, HTRA2, LETM1, LRRK2, POLG,
SIRT3, SOD1, VDAC1 have been specifically described in the
context of neuronal death in ALS. For instance, the gene
polymerase gamma (POLG), which is related to mitochondrial
biogenesis, was investigated in the context of ALS (Ladd et al.,
2014). The mitochondrial protein ATP5B was also correlated
to pathogenesis of neurodegenerative disorders (Yoon et al.,
2009), actually the Western Pacific ALS-parkinsonism-dementia
complex (Kisby et al., 2006). Mitochondrial proteins involved in
cell-cycle and transcriptional regulation, i.e., E2F1, participate
in the neuronal death pathways (Wu et al., 2012) and in
ALS (Ranganathan and Bowser, 2003). Also, impairments of
the apoptotic intermembrane mitochondrial serine protease
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HTRA2 lead to its accumulation in motor neuronal inclusions
in ALS (Kawamoto et al., 2010) and neuronal death (Patterson
et al., 2014). Importantly, the mitochondrial Ca(2+) transporter
LETM1 is elevated in death resistant motor neurons of ALS
mice. Conversely, LRRK2 was implicated in early neuronal
death (Chen et al., 2012; Chou et al., 2014) while SIRT3 may
exert neuroprotection by avoiding mitochondrial fragmentation
in ALS mouse (Song et al., 2013), indicating the complex
role of mitochondria in neurodegenerative diseases (Mühling
et al., 2014). Furthermore, dysfunction of the mitochondrial
voltage-dependent anion channel (VDAC) was associated with
neuroprotection failure (Fernandez-Echevarria et al., 2014) and
neurodegeneration in ALS (Israelson et al., 2010). Of note,
a specific pathogenic LRRK2 mutation was described in ALS
(Whittle et al., 2007). It should be noticed that the role of SOD1
in mitochondrial mechanism related to ALS has been largely
described (Dupuis et al., 2004).
Finally, the PSMC4, GRN, and ND2 encoded genes of
mitochondrial proteins have also been described in ALS, as it
is the case of the 26S proteasome regulator PSMC4 (Trippier
et al., 2014). Interestingly, a co-occurrence of GRN/C9ORF72
(Testi et al., 2015) and of NADH dehydrogenase subunit 2 (ND2)
mutations were also detected in ALS patients (Lin et al., 1992).
It should be noticed that mutations of CHCHD10 have
been described in ALS, a gene that encodes an intermembrane
mitochondrial protein involved in mitochondrial genome
stability and morphology (Bannwarth et al., 2014; Johnson et al.,
2014).
It is well known that the regulation of mitochondrial gene
expression is not restricted to pathological conditions but
instead to a large range of cellular physiological conditions.
However, we have demonstrated in our work no variations of
mitochondrial gene expression within the groups but a significant
difference between non-ALS and ALS subjects, emphasizing a
possible participation of deregulated genes in the motor neurons
disease. Actually, statistical significance between groups and
small intragroup variability indicated an homogeneity of the
samples.
qPCR Verification of Sporadic ALS Motor Neuron
Deregulated Genes
The results of the qPCR and microarray analyses correlated
well for all selected genes, confirming the efficacy of
large gene profiling in the search for therapeutic targets
in neurodegenerative disorders (de Oliveira et al., 2013;
Maximino et al., 2014). Notably, a relationship between these
deregulated genes with various molecular/biological processes
related to intracellular trafficking, intercellular signaling, and
neurotrophic functions (Vucic and Kiernan, 2009; Martin, 2012;
Chaturvedi and Flint Beal, 2013) is supportive of a role for
mitochondrial dysfunction in ALS, as previously postulated
for other neurodegenerative diseases (Pagano et al., 2014)
Furthermore, a critical analysis of the up and down regulated
genes by qPCR supports their roles in both the events initiating
neuronal damage and subsequent reactive events leading to
neuroprotection.
Of note, LETM1, which encodes a mitochondrial Ca2+/H+
exchanger protein (Waldeck-Weiermair et al., 2011; Nowikovsky
et al., 2012) was found to be up-regulated in iPSC-developed
motor neurons of sporadic ALS patients. This mitochondrial
ion exchange protein has been linked to protection of rescued
neurons in the ALS mouse model (Mühling et al., 2014), possibly
by its ability to regulate Ca2+ homeostasis. The high down
regulation of LETM1 in sporadic ALS motor neurons supports
a role for mitochondrial dysfunction in the cell-autonomous
failure of neuroprotection. Moreover, DUSP6 was the most
significantly down regulated gene identified by the microarray
analyses. This gene encodes for a dual specificity phosphatase-6
protein, which is a critical determinant of ERK signaling (Bhalla
et al., 2002), and is thus able to influence cell survival after
neurotoxicity (Hetman and Gozdz, 2004). As ERK signaling has
been implicated in ALS (Kim and Choi, 2010), a strong down-
regulation of DUSP6 in sporadic ALS motor neurons is worthy
of further investigation. Of note, despite of microarray and qPCR
have shown a down regulation ofDUSP6, the degree of regulation
demonstrated by microarray was higher than that obtained by
qPCR analysis The use of qPCR analysis to qualitatively verify the
microarray results is largely accepted in the literature. However,
small discrepancies in the degree of gene regulation between the
two methods have been reported (Ferraiuolo et al., 2007). These
methods have their specific quantitative differences (Chuaqui
et al., 2002), which are thought to be related to the variation in
the hybridization kinetics of the technologies, low fold changes or
lack of concordance between transcripts accessed in each method
(de Oliveira et al., 2013).
Dysfunction in lipid metabolism has also been associated
with ALS (Schmitt et al., 2014; Palamiuc et al., 2015).
The present study is the first to demonstrate a significant
deregulation of DGAT1, a gene which encodes a multipass
transmembrane protein that functions as a key metabolic enzyme
in the conversion of diacylglycerol and fatty acetyl CoA to
triacylglycerol, in the context of human ALS.
Also, specific processes involving potassium channels have
been described in non-autonomous glial mechanisms of ALS
(Bataveljic´ et al., 2012; Sato et al., 2014). However, this
work contributed to the original description of this potassium
channel’s (subfamily K, member 12 gene, KCNK12) deregulation
in differentiated human motor neurons from sporadic ALS
patients.
The contribution of kinesins in the deregulated axonal
transport (Landers et al., 2009; Shi et al., 2010; Kuzma-
Kozakiewicz et al., 2013) as well as the participation of
cytoskeleton components (Maximino et al., 2014) in ALS have
been well documented. However, the significant down regulation
in the genes, KIFC-1 and KRTAP4-11, point to the possibility
of abnormalities in intracellular trafficking and cytoskeletal
structural changes respectively, in the differentiated motor
neurons from sporadic ALS patients.
The up-regulation of CASP9, which encodes for caspase-
9 protein, might activate mitochondria-dependent apoptotic
signaling, an event that has been described in neurodegenerative
diseases (Andreoli et al., 2009; Darwish and Amiridze, 2010)
including ALS (Pasinelli et al., 2000; Guégan et al., 2001, 2002;
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Inoue et al., 2003). Interestingly, caspase-9 levels have been
correlated with clinical severity in ALS patients (Ilzecka, 2012).
Considering the disease-specific phenotype of the iPSC-derived
motor neurons in the present analysis, an early dysfunction
of caspase-9 mediating motor neuron death may take place in
sporadic ALS. Furthermore, the up regulation SDHAF1, which
encodes for succinate dehydrogenase complex, an enzyme that
participates in the respiratory chain and Krebs cycle (Rutter
et al., 2010) further implicates mitochondrial participation in
sporadic ALS.
Conversely, distinct from the putative roles of CASP9 and
SDHAF-1, the up-regulation of IGF2 and VPS35 may indicate
the occurrence of reactive autocrine neuroprotective responses
in the sporadic ALS-differentiated motor neurons after an initial
damage. Thus, it is likely that up-regulation of IGF2 may be
involved in neuroprotection of motor neurons (Leventhal et al.,
1999; Silva et al., 2009), in line to its previously suggested role
in non-autonomous glial ALS mechanisms (Kihira et al., 2007;
Dagvajantsan et al., 2008). The fact that IGF-1 treatment led to
neuroprotection in an ALS animal model (Jablonka et al., 2011;
Saenger et al., 2012) and to partial benefits in ALS clinical trials
(Lai et al., 1997; Borasio et al., 1998), further supports our finding
that up-regulation of IGF2 expression in the differentiated motor
neurons from sporadic ALS patients highlights the importance
of IGF family proteins as potential therapeutic targets for this
disease. Accordingly, the regulation of VPS35 corroborates our
findings with IGF2. The VPS35 gene product is involved in
retrograde transport of proteins from endosomes to the Golgi
complex (Zhang et al., 2001). VPS35 mutations and disruption
of endosomal trafficking has previously been implicated in other
neurodegenerative disorders (Small et al., 2005; Zimprich et al.,
2011; Ando et al., 2012; Vilariño-Güell et al., 2014; Perrett
et al., 2015). Thus, up-regulation of VPS35 might account for a
neuroprotective response in ALS before degeneration of motor
neurons begins.
In conclusion, the large gene profiling of early stage mature
motor neurons differentiated from hiPSCs, which in turn,
were derived from adult motor nerve associated fibroblasts
from sporadic ALS subjects, has provided evidence for a
wide range of molecular and cellular mechanisms possibly
involved in the cell autonomous neuronal death in the disease.
Of note, evidence supporting impairment of intracellular
trafficking, intercellular signaling, oxidative phosphorylation
and neurotrophic factor function among others, strongly
implicate mitochondrial dysfunction as a key factor in this cell-
autonomous neurodegeneration process. Interestingly, evidence
is also provided that autocrine neuroprotective mechanisms
coexist with those related to cell toxicity in these human sporadic
ALS differentiated motor neurons. These results thus emphasize
the importance of the use of human iPSC-derived motor
neurons, obtained from motor nerve fibroblasts, as a reliable
method to model disease mechanisms associated with neuronal
degeneration in sporadic ALS. Importantly, the approach may
also provide a viable opportunity to translate these results to
the development of potential therapeutic targets specific to
sporadic ALS.
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